Diffuse large B-cell lymphoma (DLBCL) is nowadays a curable disease with the frontline
treatment R-CHOP, but 30–40% of patients are still unresponsive or relapse thereafter. In …

Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured
with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R …

PURPOSE Patients with the activated B-cell-like (ABC) subtype of diffuse large B-cell
lymphoma (DLBCL) historically showed inferior survival with standard rituximab plus …

Purpose Rituximab (R) plus CHOP (cyclophosphamide, doxorubicin, vincristine,
prednisone) chemotherapy is the standard of care in previously untreated diffuse large B …

Diffuse large B-cell lymphoma (DLBCL) constitutes 30%–58% of non-Hodgkin's lymphoma
series. The crude incidence in Europe is 3.8/100 000/year [1]. The incidence increases with …

Diffuse large B cell lymphoma (DLBCL) is a highly heterogeneous lymphoid neoplasm with
variations in gene expression profiles and genetic alterations, which lead to substantial …

Lenalidomide is an orally active immunomodulatory drug that has direct antineoplastic
activity and indirect effects mediated through multiple types of immune cells found in the …

Purpose The standard treatment of patients with diffuse large B-cell lymphoma (DLBCL) is
rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone …

Dual expression of MYC and BCL2 by immunohistochemistry (IHC) is associated with poor
outcome in diffuse large B-cell lymphoma (DLBCL). Dual translocation of MYC and BCL2, so …

Diffuse large B-cell lymphoma (DLBCL) is a clinically heterogeneous lymphoid malignancy
and the most common subtype of non-Hodgkin's lymphoma in adults, with one of the highest …